AstraZeneca prices €2.55B bond offering, its largest UK health debt raise
What's the deal? AstraZenecaDealroom has a profile for this one. Try Dealroom → has priced a €2.55 billion bond offering through its wholly owned subsidiary AstraZeneca Finance LLCDealroom has a profile for this one. Try Dealroom →. The Cambridge-based biopharmaceutical company priced the four-tranche Eurobond sale on August 24, with the offering expected to close on September 1, subject to customary closing conditions.
The details: The notes span four maturities, from €700 million maturing in 2030 to €750 million maturing in 2038, with coupons ranging from 3.402% to 4.169%. Each tranche is fully and unconditionally guaranteed by the company. AstraZeneca said it expects to use the net proceeds "for general corporate purposes."
Who's involved? BarclaysDealroom has a profile for this one. Try Dealroom →, Goldman SachsDealroom has a profile for this one. Try Dealroom →, and Morgan StanleyDealroom has a profile for this one. Try Dealroom → acted as joint book-running managers. The notes will be issued under the company's Euro Medium Term Note programme and listed on the London Stock ExchangeDealroom has a profile for this one. Try Dealroom →'s Main Market.
Why it stands out: The raise ranks as the largest post-IPO debt deal on record among UK health companies, topping a sample of 67 such rounds. AstraZeneca framed the issuance as "aligned with the Company's long term funding strategy."
The signal: Large pharmaceutical firms are increasingly tapping euro-denominated debt markets to lock in funding across long maturities. For AstraZeneca — whose medicines reach patients in more than 125 countries — the multi-tranche structure spreads repayment out to 2038 while securing capital for broad corporate use.
Read more: news.cision.com
Image credit: MDGovpics
